A number of other brokerages have also recently weighed in on IART. Oppenheimer reissued a buy rating on shares of Integra Lifesciences in a report on Tuesday, March 19th. JMP Securities restated a buy rating and set a $62.00 price objective on shares of Integra Lifesciences in a research report on Wednesday, February 27th. Morgan Stanley set a $57.00 price target on shares of Integra Lifesciences and gave the stock a hold rating in a research report on Friday, February 22nd. Zacks Investment Research upgraded Integra Lifesciences from a hold rating to a buy rating and set a $58.00 price target on the stock in a report on Tuesday, April 23rd. Finally, Cantor Fitzgerald restated a hold rating and issued a $50.00 price objective on shares of Integra Lifesciences in a research note on Thursday, February 21st. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $58.00.
Shares of NASDAQ IART traded up $0.08 during midday trading on Thursday, hitting $51.18. The company had a trading volume of 1,670 shares, compared to its average volume of 385,958. The company has a quick ratio of 1.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.95. Integra Lifesciences has a twelve month low of $42.14 and a twelve month high of $67.50. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of 21.10, a price-to-earnings-growth ratio of 1.46 and a beta of 0.97.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.04. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The business had revenue of $359.69 million during the quarter, compared to analyst estimates of $361.12 million. During the same quarter in the previous year, the business posted $0.58 earnings per share. The company’s revenue was up .7% on a year-over-year basis. Equities research analysts expect that Integra Lifesciences will post 2.7 EPS for the current fiscal year.
In related news, Director Christian S. Schade sold 15,658 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $51.56, for a total transaction of $807,326.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC grew its stake in Integra Lifesciences by 223.0% in the first quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 446 shares during the period. Enlightenment Research LLC purchased a new position in Integra Lifesciences during the fourth quarter worth about $32,000. Fort L.P. bought a new stake in Integra Lifesciences during the fourth quarter worth about $34,000. Executive Wealth Management LLC bought a new stake in shares of Integra Lifesciences in the 4th quarter valued at about $38,000. Finally, One Wealth Advisors LLC bought a new stake in shares of Integra Lifesciences in the 1st quarter valued at about $94,000. 82.27% of the stock is owned by institutional investors and hedge funds.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
See Also: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.